Praxis Precision Medicines

News

Marcio Souza, Praxis' president and chief executive

Praxis soars on rare childhood epilepsy trial data

Praxis looks like it could be filing for approval of two products next year, after its childhood epilepsy drug delivered a win in a pivotal trial.

News

Praxis wields the axe as lead depression drug fails

Shares in Praxis Precision Medicines were in freefall today after the company's efforts to develop a new therapy for major depressive disorder (MDD) ended in failure, forcing a restructurin

News

Novartis snaps up PI3Kα breast cancer drug in $3bn deal

Novartis has agreed to buy a PI3Kα-targeting drug for breast cancer from Synnovation, a potential successor to its Piqray brand, for $2bn upfront.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Sales & Marketing

Using AI-driven synthetic personas to take your insights fur...

As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.

Praxis Precision Medicines

Editor's Picks